We offers you solutions for accurate, reproducible and qualitatively outstanding aids for patient support and patient immobilisation.
We leverage our broad base of innovative products and services to offer the most effective, state-of-the-art radiotherapy positioning solutions. Discover how we are advancing patient care in a variety of ways by exploring the information below.
We specialises in niche products in the field of innovative diagnostics. Our focus is on new methods relating to current and future diagnosis modalities.
We are driven to provide care that cures and comforts, research that informs the world, and education that enlightens and enables future generations. We proudly stand on our rich history and use it as a platform from which to embrace discovery and change.
Through our products and by bringing planning modalities such as computer tomography (CT) and positron emission tomography (PET) closer together, we can give you access to new alternatives for optimizing cancer treatment.
We are committed to making each decision, whether related to patient care, research, education or administration, based on standards that are thoughtful, informed, honest, transparent when appropriate and always respectful of privacy.
The Innovative Medicines Initiative (IMI) is a European initiative to improve the competitive situation of the European Union in the field of pharmaceutical research. The IMI is a joint initiative (public-private partnership) of the DG Research of the European Commission, representing the European Communities, and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI is laid out as a Joint Technology Initiative within the Seventh Framework Programme. Michel Goldman was the first executive director, from September 2009 until December 2014.
The Innovative Medicines Initiative is aimed towards removing research bottlenecks in the current drug development process. The IMI Joint Technology Initiative (IMI JTI), to be implemented by the IMI Joint Undertaking is meant to address these research bottlenecks. Its €2bn budget makes it the largest biomedical public-private partnership in the world.
When does disclosing a secret actually help the secret-keeper? In the world of patents and patent protection, it can be a key strategy. Most entrepreneurs understand that an invention must be truly novel to receive a patent. According to the U.S. Patent and Trademark Office (uspto.gov), an invention cannot be one that has been previously “patented, described in a printed …
The post Using Public Disclosures to Prevent Competitive Patents appeared first on Pittsburgh Life Sciences Greenhouse.
As a mentor to young professionals, hosting transatlantic partnerships represents a special honor. Transatlantic mentoring programs strengthen entrepreneurship in the U.S. and abroad. The Young Transatlantic Innovation Leaders Initiative (YTILI) connects European and Eurasian young entrepreneurs with U.S. mentors in cities across the country and is sponsored by the German Marshall Fund of the U.S. and the U.S. Department of …
The post PLSG Participates in Mentoring International Young Entrepreneurs appeared first on Pittsburgh Life Sciences Greenhouse.
PLSG Recognizes Advisory Board Member’s Selection to “30 Under 30” Class Carmelo Montalvo Serves on PLSG’s Under 40, Underserved Advisory Board PITTSBURGH (July 31, 2018)—Carmelo Montalvo, a member of the Pittsburgh Life Sciences Greenhouse (PLSG) Under 40, Underserved Advisory Board, was recently named by the Pittsburgh Business Times to its 2018 “30 Under 30” Class of civic and business leaders. …
The post PLSG Recognizes Advisory Board Member’s Selection to “30 Under 30” Class appeared first on Pittsburgh Life Sciences Greenhouse.
The United Nations defines community development as “a process where community members come together to take collective action and generate solutions to common problems.” Each of us, as individuals, plays a critical role in community development. It is up to each of us to help our communities to thrive and grow for the betterment of all members; to ensure that our region not …
The post Can you really create a “community?” appeared first on Pittsburgh Life Sciences Greenhouse.
Back in March I blogged about — and sang the praises of — the Small Business Innovation Research (SBIR) program and its companion STTR program. Together, those Federal programs provide nearly $2.5B of non-dilutive grant funding annually to technology start-ups and other small businesses. As I pointed out, there’s a regional “SBIR deficit,” meaning that while Pittsburgh’s universities are doing …
The post SBIR Road Tour Comes to Town appeared first on Pittsburgh Life Sciences Greenhouse.
With highly pathogenic H5N8 rapidly spreading throughout Europe, IDvet offers a range of highly specific and sensitive Influenza ELISAs to efficiently monitor spread of the disease. The ID Screen® Influenza H5 competitive ELISA has been validated by several European reference laboratories to detect new circulating clades, including H5N8. The test may be used to […]
The post H5N8 avian influenza outbreaks: efficient tools for disease monitoring and serotyping appeared first on IDVet.
Click on the image below to zoom or download our latest press release!
The post The only commercial NDV ELISA validated for use with HVT-ND vector vaccines! appeared first on IDVet.
IDvet offers both a nucleoprotein-based cELISA to detect antibodies against all Influenza strains, and serotype-specific cELISAs to detect potentially highly-pathogenic H5 and H7 strains. To monitor outbreaks with these kits: • Flocks found positive with the nucleoprotein cELISA are tested with the H5 or H7 ELISA. • Positive H5 or H7 results are confirmed by […]
The post Efficiently monitor Influenza outbreaks appeared first on IDVet.
The use of recombinant proteins in the ID Screen® MG and MS ELISAs allows for improved specificity, low background, earlier detection of seroconversion, and higher analytical sensitivity. In addition, no cross-reactions with other mycoplasmas have been detected. Freeze-dried positive and negative reference sera with defined titers are available for use as internal controls with this kit. Please […]
The post IDvet MG & MS ELISAs: recombinant antigens allow for improved Spe & Se appeared first on IDVet.
ID Soft™ is a fully integrated, easy-to-use software program providing convenient, flexible and comprehensive data analysis for IDScreen® poultry ELISA kits. Download the ID Soft™ technical sheet Determine titres, vaccination age and baseline values for better preventative medicine for poultry. Easily share your results: OD values may be exported to other formats, such as Excel. Optimize […]
The post ID Soft™ software now available appeared first on IDVet.
